WallStreetZenWallStreetZen

NASDAQ: CMMB
Chemomab Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CMMB stock forecasts and price targets.

Forecast return on equity

Is CMMB forecast to generate an efficient return?

Company
-190.33%
Industry
90.59%
Market
171.54%
CMMB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CMMB forecast to generate an efficient return on assets?

Company
-169.96%
Industry
27.12%
CMMB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CMMB earnings per share forecast

What is CMMB's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.53
Avg 2 year Forecast
-$0.61
Avg 3 year Forecast
-$0.57

CMMB revenue forecast

What is CMMB's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

CMMB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CMMB$1.56N/AN/A
KPRX$2.63N/AN/A
CALC$0.74$10.00+1,258.70%Buy
GDTC$1.00N/AN/A
PHIO$1.03$14.00+1,259.22%Buy
View Top Biotech Stocks

Chemomab Therapeutics Stock Forecast FAQ

What is CMMB's earnings growth forecast for 2026-2028?

(NASDAQ: CMMB) Chemomab Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.

Chemomab Therapeutics's earnings in 2026 is -$8,995,000.On average, 4 Wall Street analysts forecast CMMB's earnings for 2026 to be -$305,182,252, with the lowest CMMB earnings forecast at -$575,151,167, and the highest CMMB earnings forecast at -$12,083,008. On average, 4 Wall Street analysts forecast CMMB's earnings for 2027 to be -$349,198,923, with the lowest CMMB earnings forecast at -$654,093,485, and the highest CMMB earnings forecast at -$18,124,512.

In 2028, CMMB is forecast to generate -$325,723,365 in earnings, with the lowest earnings forecast at -$603,344,852 and the highest earnings forecast at -$24,166,015.

If you're new to stock investing, here's how to buy Chemomab Therapeutics stock.

What is CMMB's revenue growth forecast for 2026-2028?

(NASDAQ: CMMB) Chemomab Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.93%.

Chemomab Therapeutics's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast CMMB's revenue for 2026 to be $0, with the lowest CMMB revenue forecast at $0, and the highest CMMB revenue forecast at $0. On average, 4 Wall Street analysts forecast CMMB's revenue for 2027 to be $0, with the lowest CMMB revenue forecast at $0, and the highest CMMB revenue forecast at $0.

In 2028, CMMB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is CMMB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CMMB) forecast ROA is -169.96%, which is lower than the forecast US Biotechnology industry average of 27.12%.

What is CMMB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CMMB) Chemomab Therapeutics's current Earnings Per Share (EPS) is -$1.44. On average, analysts forecast that CMMB's EPS will be -$0.53 for 2026, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$0.02. On average, analysts forecast that CMMB's EPS will be -$0.61 for 2027, with the lowest EPS forecast at -$1.14, and the highest EPS forecast at -$0.03. In 2028, CMMB's EPS is forecast to hit -$0.57 (min: -$1.05, max: -$0.04).

What is CMMB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CMMB) forecast ROE is -190.33%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.